Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

Mahyar Etminan, Sudeep Gill, Ali Samii

Abstract

Objectives To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use.

Design Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease. Studies identified through Medline, Embase, International Pharmaceutical Abstracts, and the Cochrane Library.

Results Nine studies looked at all NSAIDs in adults aged >55 years. Six were cohort studies (total of 13 211 participants), and three were case-control studies (1443 participants). The pooled relative risk of Alzheimer's disease among users of NSAIDs was 0.72 (95% confidence interval 0.56 to 0.94). The risk was 0.95 (0.70 to 1.29) among short term users (<1 month) and 0.83 (0.65 to 1.06) and 0.27 (0.13 to 0.58) among intermediate term (mostly <24 months) and long term (mostly >24 months) users, respectively. The pooled relative risk in the eight studies of aspirin users was 0.87 (0.70 to 1.07).

Conclusions NSAIDs offer some protection against the development of Alzheimer's disease. The appropriate dosage and duration of drug use and the ratios of risk to benefit are still unclear.

Introduction

Pharmacological treatments of Alzheimer's disease are limited. Recent observational studies, however, have shown that use of non-steroidal anti-inflammatory drugs (NSAIDs) may protect against the development of the disease,^{1,2} possibly through their anti-inflammatory properties.³ Results of research have varied and at least one study found no effect.⁴ One limitation of the studies with negative results may have been their small sample sizes. In such circumstances, a systematic review should be able to quantify a pooled measure of effect from the existing studies. Though one previous systematic review showed a beneficial effect, it included only three studies of NSAIDs.⁵

There remain some unanswered questions. For example, we do not know whether the benefit is a class effect or whether it is restricted to specific agents; the

role of aspirin in particular has not been examined.⁴ We therefore carried out an updated meta-analysis to quantify the risk of Alzheimer's disease in NSAID users and specifically in aspirin users and to discuss the influence of the duration of use on the potential prevention of Alzheimer's disease.

Methods

Study selection—We systematically searched Medline (1966 to October 2002 via Ovid), Embase (1974 to October 2002), International Pharmaceutical Abstracts (a database extending back to 1975 that includes over 750 journals focused on drug therapy), and the Cochrane Library (issue 2, 2002) for all relevant English language articles. Firstly, medical subject heading (MeSH) terms and textwords including Alzheimer disease, dementia, and cognition disorders were entered. Secondly, we searched using the MeSH terms and textwords anti-inflammatory agents, non-steroidal, and aspirin. We then combined the two searches, retrieved all relevant articles based on consensus among authors, and searched reference lists of retrieved articles to find other potentially relevant articles.

Data extraction—We included a study if it had clearly stated diagnostic criteria for the outcome of Alzheimer's disease or dementia and explicitly described exposure to NSAIDs. Studies also had to present data on relative risks or odds ratios or had to at least present enough data to allow these to be calculated. We excluded studies that examined exposure to other analgesics, studies in which vascular dementia was the primary outcome as the biology of this condition differs from that of Alzheimer's disease,⁶ and those that might have results duplicated elsewhere as the inclusion of duplicate results can seriously impair the validity of a meta-analysis.⁷ If two studies used the same study population during the same time period we included only the study with the stronger design (for example, larger sample size, longer follow up, better control of confounding factors). We defined use of NSAIDs as any use any time during the study period. For those studies that explicitly classified NSAID use with respect to duration of exposure, we attempted to classify use as either short, intermediate, or long term (see table 4). All studies were reviewed by

Department of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A1

Mahyar Etminan
epidemiologist

Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Department of Health Policy, Management and Evaluation, University of Toronto, Canada M6A 2E1
Sudeep Gill
fellow and geriatrician

Department of Neurology, University of Washington, Seattle, Washington 98195, USA

Ali Samii
assistant professor

Correspondence to: M Etminan
mahyar.etminan@mail.mcgill.ca

bmj.com 2003;327:128

Table 1 Characteristics of cohort studies evaluating role of NSAIDs and aspirin in preventing Alzheimer's disease. All were community studies

Study	No	Age (years)	Diagnosis of Alzheimer's disease	NSAID assessment	Variable adjustment	Event rate (cases/person years) with NSAIDs v non-NSAIDs	Adjusted relative risk or odds ratio (95% CI)	
							NSAID	Aspirin
In't Veld ¹	6989	>55	Clinical investigation	Prescription database	Age, sex, smoking, education, diabetes, antihypertensives, acid blockers	184/29 359 v 210/16 715	0.86 (0.66 to 1.09)	1.3 (0.97 to 1.74)
Zandi ²	3227	>65	Interviews and clinical investigation	Patient interviews	Age, sex, APOE gene, education	79/7048 v 22/3017	0.67 (0.40 to 1.06)	0.82 (0.54 to 1.23)
Stewart ²¹	1686	<65	Clinical investigation	Patient interviews	Age, sex, education, year of cohort entry	Only adjusted relative risks presented	0.46 (0.24 to 0.86)	0.85 (0.53 to 1.37)
Fourrier ⁴	516	>65	MMSE scores†	Patient interviews	Age, education	Only adjusted relative risks presented	2.84 (0.99 to 8.10)	—
Henderson ²³	588	80*	Interviews and clinical investigation	Patient interviews	Age, sex, education, stroke, APOE gene, arthritis medication	Only adjusted relative risks presented	1.66 (0.64 to 4.32)	1.79 (0.72 to 4.45)
Breitner 1995 ²⁴	205	NS	Interviews and autopsy	Patient interviews	Age, sex, acid blockers, insulin	Only adjusted relative risks presented	0.19 (0.02 to 1.49)	0.37 (0.17 to 0.79)

NS=not stated, all older adults. APOE=apolipoprotein E. *Mean age. †Folstein mini-mental state examination.

two of the authors (AS, ME), and discrepancies were resolved by consensus with the third author (SG).

Analysis—We carried out three separate analyses. Firstly, we selected studies that explored the risk of Alzheimer's disease in users of all NSAIDs. Secondly, we looked at the risk of Alzheimer's disease specifically among aspirin users. Thirdly, we looked at the risk of Alzheimer's disease according to duration of use of NSAIDs. We used the random effects model to calculate pooled relative risks and 95% confidence intervals as this model accounts for heterogeneity between studies.⁸ Odds ratios were considered an approximation of relative risks. We combined relative risks (from cohort studies) and odds ratios (from case-control studies) only if the result of the Q test of heterogeneity was negative. Because tests of heterogeneity may be underpowered to detect heterogeneity between studies when the number of studies is small (for instance, <20),⁹ we also explored heterogeneity graphically¹⁰ and quantitatively using the R(I) statistic.¹¹ This allows the investigator to determine whether classic tests of heterogeneity would have sufficient power to detect heterogeneity between studies. Publication bias was assessed with a funnel plot. The analyses were done with HEpiMA version 2.3.¹²

Results

We identified 15 potential studies.^{1 2 4 13–24} We excluded one study¹³ because the data in it were used in a more recent cohort study.² We excluded two other studies^{14 15} because they were case-control studies that used a population of Rotterdam residents recently used in a larger cohort study.¹ Four studies looked at the risk of

Alzheimer's disease or vascular dementia relative to NSAIDs use, but all used overlapping patient data from the same database (the Canadian Study of Health and Aging).^{16–19} We chose one of these articles for inclusion for the first analysis as it provided the largest sample size of patients across Canada.¹⁹ However, for the second analysis (confined to aspirin users) we included the only study among the four that provided data specifically on aspirin use in patients with Alzheimer's disease.¹⁷ Only two of the 15 studies provided data specifically on the outcome of vascular dementia,^{1 18} so we did not analyse this outcome separately. Four studies provided data on the effects of duration of treatment.^{1 2 21 24}

We included nine studies in the analysis of use of any NSAID.^{1 2 4 19–24} Six were cohort studies (13 211 participants, table 1)^{1 2 4 21 23 24} and three were case-control studies (1443 participants, table 2).^{19 20 22} We included eight studies for the analysis of aspirin users,^{1 2 17 20–24} of which five were cohort studies^{1 2 21 23 24} and three were case-control studies^{17 20 22} (table 3). The pooled relative risk of Alzheimer's disease was 0.84 (0.54 to 1.05) among users of NSAIDs in the cohort studies, 0.62 (0.45 to 0.82) among users of NSAIDs in the case-control studies (table 3), and 0.72 (0.56 to 0.94) in both (fig 1). The pooled relative risk for aspirin users was 0.87 (0.70 to 1.07, P=0.79 for heterogeneity). Only the study by In't Veld et al had a category for "short term" (<1 month) use.¹ The relative risk of Alzheimer's disease for this category was 0.95 (0.70 to 1.29). For intermediate and long term NSAID users the relative risks were 0.83 (0.65 to 1.06, P=0.34 for heterogeneity) and 0.27 (0.13 to 0.58, P=0.06 for heterogeneity), respectively (table 4).

Table 2 Characteristics of case-control studies evaluating role of NSAIDs and aspirin in preventing Alzheimer's disease

Study (setting)	No	Age	Diagnosis of Alzheimer's disease	NSAID assessment	Variable adjustment	Cases	Controls	Adjusted relative risk or odds ratio (95% CI)	
								NSAID	Aspirin
Breitner 1994 ²² (WW II twins)	46	75*	Telephone interview	Questionnaire	None	Only crude OR presented		0.50 (0.10 to 2.23)	0.56 (0.16 to 1.81)
Lindsay ¹⁷ (community) †	4915	>70	Clinical investigation	Questionnaire	Age, sex, education	45/152	1224/3086	—	0.85 (0.55 to 1.31)
CSHA ¹⁹ (community and institution)‡	793	>65	Clinical investigation	Questionnaire	Age, sex, education, community or hospital status	61/224	205/529	0.55 (0.37 to 0.82)	—
Beard ²⁰ (community)	604	>65	Medical records	Medical records	Age and sex matched	9/155	18/157	0.79 (0.20 to 1.38)	0.90 (0.51 to 1.59)

WW II=second world war. *Mean age. †Only data on aspirin used from this study. ‡Canadian study of health and ageing.

Fig 1 Relative risks (95% confidence intervals) from studies of NSAID use and effect on Alzheimer's disease

The results from cohort studies and case-control studies were generally similar for both analyses (table 3), with little statistical heterogeneity. We did, however, find slight heterogeneity among the cohort studies for any NSAID use. The source of this heterogeneity was the study by Fourrier et al,⁴ possibly because they diagnosed dementia using the Folstein mini-mental state examination. This has limited accuracy in distinguishing between early Alzheimer's disease and normal cognition.²⁵ Despite the relatively small number of studies, funnel plot analysis did not indicate significant publication bias (fig 2).

Discussion

Our results, based on analysis of a large number of patients, show that use of an NSAID lowers the risk of developing Alzheimer's disease. The magnitude of this benefit is consistent with that found in a recent large study with long follow up data.¹ Our results also show a greater benefit with long term rather than intermediate term use (table 4). This may be one explanation for the lack of benefit seen in two of the studies included in this review^{4, 23} in which participants were followed up for a relatively short period and therefore may not have had enough time to benefit from the protective effects of NSAIDs. An editorial by Breitner and Zandi suggested that there may be an association between duration and response for NSAIDs in preventing Alzheimer's disease, with at least two years of exposure necessary to obtain full benefit.³

Table 3 Characteristics of studies of aspirin and Alzheimer's disease

Study	No	Pooled relative risk or odds ratio (95%CI)	P value for heterogeneity	R(I) statistic
NSAIDs				
Cohort studies	6	0.84 (0.54 to 1.05)	0.04	0.58
Case-control studies	3	0.62 (0.45 to 0.82)	0.55	0.00
All studies	9	0.72 (0.56 to 0.94)	0.06	0.49
Aspirin				
Cohort studies	5	0.85 (0.71 to 1.03)	0.76	0.00
Case-control studies	3	0.84 (0.61 to 1.16)	0.77	0.00
All studies	8	0.87 (0.70 to 1.07)	0.79	0.00

The meta-analysis also indicates that aspirin has a protective effect, although this result was not significant (table 3), probably because of the small number of studies that specifically evaluated the effects of aspirin. There are theoretical reasons why aspirin may differ from other NSAIDs in terms of effectiveness.^{26, 27} At present, however, there are insufficient data on which to base any comparisons between aspirin and other NSAIDs in the prevention of dementia.

Although a few small randomised controlled trials have shown some beneficial effects on cognition with use of NSAIDs in patients with established Alzheimer's disease,^{28, 29} no randomised controlled trial to date has looked at the prevention. Currently the relative benefit of COX 2 selective inhibitors over traditional NSAIDs is purely speculative. However, studies are now underway to determine the role of COX 2 selective inhibitors in the prevention of Alzheimer's disease.^{30, 31}

Limitations of study

Publication bias may have influenced our results because negative studies are less likely to be published.

Fig 2 Funnel plot of studies of NSAID use and Alzheimer's disease (0 on the x axis (natural logarithm of relative risk) represents null effect). Visual inspection of funnel plot does not indicate publication bias

Table 4 Relative risks (95% confidence interval) for NSAID users, stratified by length of use

Study	Short term (<1 month)	Intermediate term	Long term
In't Veld ¹	0.95 (0.70 to 1.29)	0.83 (0.62 to 1.11) (>1-23 months)	0.20 (0.05 to 0.83) (≥24 months)
Zandi ²	—	1.23 (0.54 to 2.46) (≤24 months)	0.51 (0.18 to 1.15) (>24 months)
Stewart ²¹	—	0.65 (0.33 to 1.29) (<24 months)	0.40 (0.19 to 0.84) (>24 months)
Breitner ²⁴	—	0.19 (0.02 to 1.49) (>1-12 months)	0.08 (0.02 to 0.26)* (>12 months)
Pooled relative risk	0.95 (0.70 to 1.29)	0.83 (0.65 to 1.06)	0.27 (0.13 to 0.58)

*Narrow confidence interval may result from larger proportion of participants exposed for >12 months (17/142) than proportion exposed for 1-12 months (4/129) in original paper. We performed sensitivity analysis by calculating pooled RR for long term users with and without Breitner study to examine effect on results. Pooled RR for long term users changed to 0.4 (0.24 to 0.67), which does not change our findings.

What is already known on this topic

Few treatments exist for people with Alzheimer's disease, and recent efforts have focused on preventive measures

Observational studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) protect against Alzheimer's disease, but results have been inconsistent

What this study adds

Use of NSAIDs seems to lower the risk of developing Alzheimer's disease in adults aged >55 years

Benefits may be greater the longer NSAIDs are used

The evidence behind the potential preventive use of aspirin is not robust

Although this trend does not seem to be reflected in our funnel plot we cannot exclude it as the funnel plot may not detect publication bias when the number of studies is small. Secondly, the possibility of confounding and bias may be more significant in meta-analyses of observational studies than in meta-analyses of randomised trials, and statistical adjustment for confounding variables in observational studies may not entirely resolve these problems. Case-control studies are particularly at risk of biased patient selection that may unduly weight the outcome in favour of the exposure under evaluation. In our review, the case-control studies all tended to support NSAIDs having a protective effect, while the cohort studies had more variable results (fig 1). Another relevant bias is recall bias as in some of the studies information on NSAID use was obtained by interviewing patients.

There were important differences in study design, including the assessment of exposure and adjustments for confounding factors (see tables 1 and 2). Adjustments were not always made for important risk factors for Alzheimer's disease such as family history and apolipoprotein E status. These differences in study design may give rise to clinical heterogeneity, which may not be fully reflected in the results of our statistical tests of heterogeneity. Finally, the restriction of our systematic review to English language studies may have resulted in language bias with potentially relevant studies published in other languages being missed.³²

Conclusion

In light of the growing evidence from observational studies and the current absence of evidence from randomised controlled trials, our systematic review lends support to the hypothesis that NSAIDs may protect against the development of Alzheimer's disease. The appropriate dose, duration, and ratios of risk to benefit are still unclear.

We thank Paula Rochon (Kunin-Lunenfeld Applied Research Unit and Department of Health Policy, Management and Evaluation, University of Toronto, Canada) for reviewing the manuscript.

Contributors: ME and AS initiated the project. ME, SG, and AS screened and extracted the data. ME and SG analysed the data.

All authors participated in discussing the results and in writing the paper. ME will act as guarantor for the paper.

Funding: AS is funded by a Parkinson Disease Research Education and Clinical Center (PADRECC) grant. ME and SG are funded by Canadian Institutes of Health Research (CIHR) post-doctoral fellowship awards. The guarantor accepts full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish.

Competing interests: None declared.

- 1 In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *N Engl J Med* 2001;345:1515-21.
- 2 Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Brietner JC, et al. Reduced incidence of AD with NSAID but not H₂ receptor antagonists: the Cache County study. *Neurology* 2002;59:880-6.
- 3 Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? *N Engl J Med* 2001;345:1567-8.
- 4 Fourrier A, Letenneur L, Begaud B, Dartigues JF. Nonsteroidal anti-inflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. *J Clin Epidemiol* 1996;49:1201.
- 5 McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology* 1996;47:425-32.
- 6 Amar K, Wilcock G. Vascular dementia. *BMJ* 1996;312:227-31.
- 7 Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. *Lancet* 1996;347:1024-6.
- 8 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-88.
- 9 Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. *Stat Med* 1998;17:841-56.
- 10 Walker AM, Martin-Moreno JM, Artalejo FR. Odd man out: a graphical approach to meta-analysis. *Am J Public Health* 1988;78:961-6.
- 11 Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. *Am J Epidemiol* 1999;150:206-15.
- 12 Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, Spiegelman D. HEpiMA: software for the identification of heterogeneity in meta-analysis. *Comput Methods Programs Biomed* 2001;64:101-7.
- 13 Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, et al. Reduced prevalence of AD in users of NSAIDs and H₂ receptor antagonists: the Cache County study. *Neurology* 2000;54:2066-71.
- 14 Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. *Neurology* 1995;45:1441-5.
- 15 In't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, et al. NSAIDs and incident Alzheimer's disease. The Rotterdam study. *Neurobiol Aging* 1998;19:607-11.
- 16 Wolfson C, Perrault A, Moride Y, Esdaile JM, Abenham L, Momoli F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? *Neuroepidemiology* 2002;21:81-6.
- 17 Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. *Am J Epidemiol* 2002;156:445-53.
- 18 Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. *Stroke* 2000;31:1487-93.
- 19 The Canadian study of health and aging: risk factors for Alzheimer's disease in Canada. *Neurology* 1994;44:2073-80.
- 20 Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokman E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. *Mayo Clin Proc* 1998;73:951-5.
- 21 Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. *Neurology* 1997;48:626-32.
- 22 Breitner JC, Gau MW, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease. *Neurology* 1994;44:227-32.
- 23 Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE. Aspirin, anti-inflammatory drugs and risk of dementia. *Int J Geriatr Psychiatry* 1997;12:926-30.
- 24 Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H₂ blocking drugs. *Neurobiol Aging* 1995;16:523-30.
- 25 Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. *Neurology* 2000;55:1847-53.
- 26 Ho L, Purohit D, Haroutunian V, Luteranman JD, Willis F, Naslund J, et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. *Arch Neurol* 2001;58:487-92.
- 27 Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used non steroidal anti-inflammatory drugs. *Am J Med* 1998;104:413-21.
- 28 Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. *Neurology* 2002;58:1050-4.
- 29 Scharf S, Mander A, Ugioni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. *Neurology* 1999;53:197-201.
- 30 Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. *J Pain Symptom Manage* 2002;23:S35-40.

- 31 Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;58:1985-92.
- 32 Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes

G. Language bias in randomised controlled trials published in English and German. *Lancet* 1997;350:326-9.

(Accepted 6 May 2003)